Trauma-induced coagulopathy (TIC) has been identifi ed early after patient presentation [2] , is associated with shock and massive transfusion (MT) requirements, may occur in the absence of coagulation factor depletion [3] , and has been reported to complicate up to 30% of major trauma admissions [4] . Accordingly, early and accurate diagnosis of TIC is essential to facilitate and optimize rapid provision of appropriate blood products in order to decrease morbidity and mortality, to promote effi cient utilization of valuable resources, and to avoid wastage of nonessential therapy.
Conventional coagulation testing (CCT) remains the predominant method of assessing coagulation status worldwide, including the prothrombin time, activated partial thromboplastin time, platelet tests, and fi brinogen concentration. Despite this predominance, these tests have never been proven accurate in the hemorrhaging trauma patient [5] and suff er from a prolonged laboratory turnaround time of 1 hour or more in certain settings [6] . Finally, since they are plasma based, the assays do not accurately refl ect the physiological milieu of whole blood, where multiple elements -including endothelium, platelet interactions, and subsequent thrombin generation -contribute to ultimate clot strength, leading to a meticulous balance of hemostasis and lysis. Accordingly, there has been recent growing enthu siasm for alternate methods of coagulation assessment.
Th romboelastography (TEG®; the name is a trademark of Haemoscope Corp. USA) and thromboelastometry (ROTEM®; the name is a trademark of Tem Innovations GmbH, Munich, Germany) tests that assess the viscoelastic properties of whole blood are relatively newer members of the diagnostic armamentarium currently under investigation for the assessment of patients at risk for TIC [7, 8] . Both tests provide the potential to supersede CCT in the diagnosis of TIC because they provide real-time assessment of clot physiology from initial activation, subsequent achievement of tensile strength, and eventual resolution/degradation via a graphical tracing of fi brin polymerization and clot strength. Beyond the early diag nosis of TIC via point-of-care assessment, perhaps the most promising future for TEG®/ Abstract Thromboelastography and thromboelastometry represent viscoelastic diagnostic methodologies with promising application to diseases of altered coagulation. Their use in trauma-induced coagulopathy as a means of assessing the real-time status of the patient's functional coagulation profi le in addition to its impact on eff ective and appropriate use of blood product support has been gaining acceptance among trauma surgeons, anesthesiologists, and transfusion medicine specialists. However, the ability of viscoelastic testing to augment or supplant conventional coagulation testing for the diagnosis and management of trauma-induced coagulopathy remains controversial. Many of these issues pertain to the diff erences in methodology, instrumentation, logic, accessibility, ease of use, operator variability, and the method's relationship to patient care, blood product use, cost, and conventional testing algorithms. ROTEM® technology is the additional potential benefi t of early goal-directed therapy, with the objective to optimize and possibly reduce blood product utilization [9] . In the present issue of Critical Care, Schöchl and colleagues evaluated whole blood ROTEM® assays and the test's ability to predict those seriously injured patients (all with Injury Severity Score >16) likely to require MT (>10 units red blood cells/24 hours) during the subsequent hospitalization [1] . Utilizing a variety of assays (extrinsically activated assay with tissue factor, intrinsically activated assay using ellagic acid, and fi brin-based extrinsically acti vated assay with tissue factor and the platelet inhibi tor cytochalastin D), the authors assessed the clotting time, clot formation time, clot amplitude at the end of the clotting time, and maximum clotting fi rmness, and compared the predictive value of these tests with CCT and other physiologic parameters. Although Schöchl and colleagues noted that the best predictive tests for MT were a simple hemoglobin or Quick value, they observed that the predictive values of the clot amplitude at the end of the clotting time and the maximum clotting fi rmness for the fi brin-based extrinsically activated assay with tissue factor and the platelet inhibitor cytochalastin D were similar, with the chief advantage being the availability of results within 10 minutes.
At fi rst glance, the astute clinician may argue that severely injured patients at risk for TIC can already be identifi ed via CCT or clinical factors, such as a variety of scoring systems [10, 11] , and hence why the need for another potentially expensive test to provide the same information albeit somewhat earlier? Accordingly, as with many excellent studies, the fi ne details raise more questions than provide answers. As pointed out by the authors, the rapid availability of point-of-care whole blood assays aff ords a much more comprehensive assess ment of the true relational hemostatic state of the individual patient. For instance, hyperfi brinolysis -which has recently been described by several investigators in the trauma setting [12] [13] [14] and can only be rapidly identifi ed via viscoelastic tests -was clearly noted in 19 patients. Furthermore, the mean fi brinogen level in the MT group was 95 mg/dl. Given the emerging signifi cance of hyperfi brinolysis in the pathophysiology of TIC [12] , and the current use of fi brinogen concentrates for resuscitation in European centers, it would be interesting for the authors to correlate the frequency of this phenomenon in the MT group and its association with the fi brinogen level and clot strength. Furthermore, recent evidence supporting early use of antifi brinolytics [15] has prompted many centers to now include such therapy as a fi rst-line adjunct to their MT protocols.
Schöchl and colleagues are to be congratulated for this important work, and we agree that current evidence continues to grow in support of point-of-care viscoelastic analysis of coagulation status. Of note, however, the appli cation and adaption of this technology present signifi cant challenges. For instance, it should be noted that the authors' group have been working with these tech niques for some time, and have no doubt moved beyond a signifi cant learning curve for use of these techniques. Furthermore, recognizing the complex inter actions of the hemostatic system, we posit that that TEG®/ROTEM® should be considered as a tool to better appre ciate relational hemostatic mechanisms that probably coexist in TIC. While we agree with the authors that ROTEM® can aff ord the clinician/surgeon a rapid diag nosis of TIC, it must be noted that ROTEM®-based assess ments were similar to CCT when only simply applied for predicting MT.
In sum, the authors have clearly shown that TEG®/ ROTEM® holds promise as an important tool for the rapid diagnosis of TIC. We encourage the authors to continue their investigations, moving beyond observational trials to therapeutic interventions, utilizing this technology to improve our understanding of the complex physiologic changes to the coagulation system induced by signifi cant injury. Such progress will fi rmly establish viscoelastic analyses as a notable and valiant member of the diagnostic roundtable.
